Oberg K - Search Results

1

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.

Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki MJ, Oberg K, Knigge U. Janson ET, et al. Among authors: oberg k. Acta Oncol. 2010 Aug;49(6):740-56. doi: 10.3109/0284186X.2010.492791. Acta Oncol. 2010. PMID: 20553100 Review.

2

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.

Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M; Nordic NE Tumour Group. Oberg K, et al. Acta Oncol. 2004;43(7):617-25. doi: 10.1080/02841860410018575. Acta Oncol. 2004. PMID: 15545182

3

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.

Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M; Nordic NE Tumour Group. Oberg K, et al. Acta Oncol. 2004;43(7):626-36. doi: 10.1080/02841860410018584. Acta Oncol. 2004. PMID: 15545183

4

Gastrin-releasing-peptide in neuroendorine tumours.

Granberg D, Skogseid B, Welin S, Orlefors H, Oberg K, Wilander E. Granberg D, et al. Among authors: oberg k. Acta Oncol. 2006;45(1):23-7. doi: 10.1080/02841860500367434. Acta Oncol. 2006. PMID: 16464792

5

Malignant neuroendocrine tumors.

Janson ET, Oberg K. Janson ET, et al. Among authors: oberg k. Cancer Chemother Biol Response Modif. 2002;20:463-70. Cancer Chemother Biol Response Modif. 2002. PMID: 12703220 Review. No abstract available.

6

Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.

Janson ET, Oberg K. Janson ET, et al. Among authors: oberg k. Cancer Chemother Biol Response Modif. 2003;21:535-46. Cancer Chemother Biol Response Modif. 2003. PMID: 15338762 Review. No abstract available.

7

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.

Janson ET, Oberg K. Janson ET, et al. Among authors: oberg k. Acta Oncol. 1993;32(2):225-9. doi: 10.3109/02841869309083916. Acta Oncol. 1993. PMID: 7686765 Clinical Trial.

8

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.

Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK. Welin SV, et al. Among authors: oberg ke. Eur J Endocrinol. 2004 Jul;151(1):107-12. doi: 10.1530/eje.0.1510107. Eur J Endocrinol. 2004. PMID: 15248829 Clinical Trial.

9

PET in the diagnosis of neuroendocrine tumors.

Sundin A, Eriksson B, Bergström M, Långström B, Oberg K, Orlefors H. Sundin A, et al. Among authors: oberg k. Ann N Y Acad Sci. 2004 Apr;1014:246-57. doi: 10.1196/annals.1294.027. Ann N Y Acad Sci. 2004. PMID: 15153441 Review.

10

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B. Ekeblad S, et al. Among authors: oberg k. Clin Cancer Res. 2007 May 15;13(10):2986-91. doi: 10.1158/1078-0432.CCR-06-2053. Clin Cancer Res. 2007. PMID: 17505000

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

701 results

Search Page